renal-cell-carcinoma

Documents about renal-cell-carcinoma

• The role of pathology in immunotherapy and targeted therapy for renal cell carcinoma#268874IRIS
• Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy#811158ClinicalTrials.gov
• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma#901633ClinicalTrials.gov
• Bilateral renal cell carcinoma with leiomyomatous stroma: a rare entity diagnosed synchronously and treated surgically in a staged fashion#954944Koc University Digital Collections
• Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy#908552ClinicalTrials.gov
• Study In Patients With Kidney Cancer Treated With Sutent#377331ClinicalTrials.gov
• Novel Prognostic Markers in Renal Cancer#880056ClinicalTrials.gov
• CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma#1029774ClinicalTrials.gov
• TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy#314343ClinicalTrials.gov
• A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer#152519ClinicalTrials.gov
• Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma#857880ClinicalTrials.gov
• Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer#874845ClinicalTrials.gov
• Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer#968088ClinicalTrials.gov
• A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma#881062ClinicalTrials.gov
• Molecular Mechanisms of 24-Methyl Cholesterol a Therapeutic Agent in Clear Cell Renal Cell Carcinoma via Modulation of Cellular Glucose Metabolism#212231Scholars Crossing
• Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide Cohort#262194HAL (France)
• Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)#842750ClinicalTrials.gov
• A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)#859630ClinicalTrials.gov
• Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions#869614ClinicalTrials.gov
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors#180367ClinicalTrials.gov
• A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)#840894ClinicalTrials.gov
• ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses#812844ClinicalTrials.gov
• Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2#829255ClinicalTrials.gov
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors#158233ClinicalTrials.gov
• The Cold Ischemia Robot-assisted Partial Nephrectomy#848058ClinicalTrials.gov
• Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation#917973ClinicalTrials.gov
• Spanish Real-World Evidence Cabozantinib#353266ClinicalTrials.gov
• Sutent Rechallenge In mRCC Patients#825528ClinicalTrials.gov
• Genetic Susceptibility to Kidney Cancer#886788ClinicalTrials.gov
• Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma#841460ClinicalTrials.gov
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma#123459ClinicalTrials.gov
• CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)#980038ClinicalTrials.gov
• Enzalutamide Before Surgery in Treating Patients With Kidney Cancer#807045ClinicalTrials.gov
• Cancer and Blood Pressure Management, CARISMA Study#201644ClinicalTrials.gov
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study#850211ClinicalTrials.gov
• Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine#454035ClinicalTrials.gov
• Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.#885134ClinicalTrials.gov
• Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer#969025ClinicalTrials.gov
• Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)#1045771ClinicalTrials.gov
• A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)#899772ClinicalTrials.gov
• Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer#825013ClinicalTrials.gov
• Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab#369832ClinicalTrials.gov
• Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer#980954ClinicalTrials.gov
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors#842594ClinicalTrials.gov
• Renal Cell Carcinoma Metastases to Pancreas#894565ClinicalTrials.gov
• Quantifying Systemic Immunosuppression to Personalize Cancer Therapy#861951ClinicalTrials.gov
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery#982103ClinicalTrials.gov
• Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma#5163Europe PMC
• Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)#123628ClinicalTrials.gov
• Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment#897480ClinicalTrials.gov